Expertise in
5
conditions

Elisabeth Ejerblad

Uppsala, C, SE 
Expertise in
5
conditions
Uppsala, C, SE 

Overview

Elisabeth Ejerblad practices practicing medicine in Uppsala, Sweden.

Ms. Ejerblad is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Polycythemia Vera, Essential Thrombocythemia, Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 18 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Uppsala, C, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open Pilot Study to Assess the Pharmacokinetics, Tolerability, and Safety of NEX-18a Given as a Subcutaneous Injection for the Treatment of Intermediate 2 or Higher-risk MDS, CMML or AML
An Open Pilot Study to Assess the Pharmacokinetics, Tolerability, and Safety of NEX-18a Given as a Subcutaneous Injection for the Treatment of Intermediate 2 or Higher-risk MDS, CMML or AML
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drugs: NEX-18a Injection, Azacitidine Injection
Study Phase: Phase 1
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
View 1 Less Clinical Trial

18 Total Publications

Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study.
Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study.
Journal: British journal of haematology
Published: August 08, 2025

Frequently Asked Questions about Elisabeth Ejerblad

Is Elisabeth Ejerblad a top-rated expert for Polycythemia Vera?

MediFind is an objective health platform that identifies experts based on real-world data. Elisabeth Ejerblad is classified as an Advanced expert for Polycythemia Vera, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Elisabeth Ejerblad participate in research or clinical trials?

Yes. Elisabeth Ejerblad has published 18 articles and abstracts on conditions like Polycythemia Vera. You can view a list of Elisabeth Ejerblad's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ejerblad's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile